• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ACR
Click for more information
1.59% 6.4¢

ACRUX LIMITED - Charts / Financials

Market Cap $18.60M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is... Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto(estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 15.56pm 10/05/2024 (20 minute delay) ?
Day
Open 6.4¢   Day High 6.6¢   Day Low 6.3¢
Daily Volume 432392
Bids   Sellers
Number Price Volume   Number Price Volume
1 6.3¢ 3828   1 6.4¢ 214977

Directors & Senior Management

Mr. Michael John Kotsanis Chief Executive Officer, Managing Director, Executive Director
Ms. Joanna Johnson Chief Financial Officer, Company Secretary
Ms. Felicia Colagrande Product Development and Technical Affairs Director
Mr. Mark Hyman Project and Technical Development Director
Mr. Ross Dobinson Independent Non-Executive Chairman of the Board
Dr. Geoffrey E. D. Brooke Independent Non-Executive Director
Mr. Don Brumley Independent Non-Executive Director
Dr. Timothy Charles Oldham Independent Non-Executive Director

Data source: Refinitiv

(20min delay)
Last
6.4¢ 		Change
0.001(1.59%) 		Mkt cap ! $18.60M
Open High Low Value Volume
6.4¢ 6.6¢ 6.3¢ $27.96K 432.3K

Buyers (Bids)

No. Vol. Price($)
1 3828 6.3¢
 

Sellers (Offers)

Price($) Vol. No.
6.4¢ 214977 1
View Market Depth
Last trade - 16.10pm 10/05/2024 (20 minute delay) ?
Last
6.3¢ 		  Change
0.001 ( 0.00 %)
Open High Low Volume
6.5¢ 6.7¢ 6.3¢ 79044
Last updated 15.56pm 10/05/2024 ?

Top Stories

Prominence impresses the market with uranium grading 5,269ppm in Kazakhstan

Prominence Energy has seen shares rise 33% on news of uranium grading up to 5,269ppm from early sampling work in Kazakhstan.
CBA profits fall 3% in March quarter but funding portfolio is flourishing Commonwealth Bank has reported a 3 percent fall in profits for the March quarter of 2024, compared to the previous quarter.
UNITH's digital humans expand into Amazon; Facebook AI-powered 'Digital Human' chatbot developer UNITH has announced its in-house tech can now harmonise with that used by Facebook and Amazon.
Raiden opens door to private Mallina in win-win Arrow Gold divestment Raiden Resources has announced its execution of a farm-in deal on-site Raiden's non-core asset, the Arrow gold project.
Recce breathes better on positive lung infection drug pilot test results Recce Pharmaceuticals Ltd has revealed positive results from its pilot test on synthetic drug Recce 327, which aims to treat lung infections.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.